ReviewMediterranean journal of hematology and infectious diseases2021
Pediatric Mastocytosis: An Update.
Review in Mediterranean journal of hematology and infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Sleep disturbances and dermatology-related quality of life in children with cutaneous mastocytosis: a patient-centered perspective.European journal of pediatrics · 2026Article
- Low BMD is uncommon in pediatric mastocytosis: a DEXA- based cohort study.European journal of pediatrics · 2026Article
- Molecular characterization of pediatric mastocytosis revealed different somatic mutations with uncertain prognostic value.Frontiers in cell and developmental biology · 2026Article
- Clinicopathological Features and Prognosis of Pediatric Mastocytosis: A 15-Year Experience with Emphasis on Disease Evolution.Clinical, cosmetic and investigational dermatology · 2026Article
- A Telangiectasia Macularis Eruptiva Perstans in a Child: A Rare Vascular Phenotype of Cutaneous Mastocytosis.Case reports in pediatrics · 2026Article
- Hereditary α-Tryptasemia and Peripheral BloodInternational journal of molecular sciences · 2025Article
- Mastocytosis in a Case of Noonan Syndrome Caused by a De Novo PathogenicYonago acta medica · 2023Article
- A Review of the Clinical Features and Management of Systemic Congenital Mastocytosis through the Presentation of An Unusual Prenatal-Onset Case.Current oncology (Toronto, Ont.) · 2023Review
- Cutaneous Mastocytosis in Childhood: An Update from the Literature.Journal of clinical practice and research · 2023Review
- The role of phototherapy in pediatric dermatology.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mastocytosis is a rare clonal disorder characterized by excessive proliferation and accumulation of mast cells (MC) in various organs and tissues. Cutaneous mastocytosis (CM), the most common form in children, is defined when MC infiltration is limited to the skin. In adults, the most common form is systemic mastocytosis (SM), characterized by MC proliferation and accumulation in organs, such as bone marrow, lymph nodes, liver, and spleen.1 Genetic aberrations, mainly the KIT D816V mutation, play a crucial role in the pathogenesis of mastocytosis, enhancing MC survival and subsequent accumulation in organs and tissues.2,3 CM includes three forms: solitary mastocytoma, maculopapular cutaneous mastocytosis (MPCM), and diffuse cutaneous mastocytosis (DCM). In most children with CM, skin lesions regress spontaneously around puberty; unfortunately, it is not always a self-limiting disease.4 Even if SM occurs occasionally, all children with mastocytosis require planned follow-up over time. Children with mastocytosis often suffer from MC mediator-related symptoms, the most common of which is itching, often triggered by rubbing the lesions. Management of pediatric mastocytosis is mainly based on strict avoidance of triggers. Treatment with H1 and H2 histamine receptor blockers on demand and the availability of epinephrine auto-injectors for the patients to use in case of severe anaphylactic reactions are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.